NASDAQ:VRDN
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE's revenue grew 23359.9% in fiscal 2025 to $70.8M while operating margin rose to −512.9%. Free cash flow was −$276.9M, −390.8% of revenue.Summary generated from Viridian Therapeutics, Inc.\DE's SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$70.8M
Revenue growth+23359.9%
Revenue, 5-yr CAGR+132.2%
Gross marginn/a
Operating margin−512.9%
Net margin−483.6%
ROICn/a
Return on equity−49.2%
Debt / equityn/a
Free cash flow−$276.9M
FCF margin−390.8%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 2 | 0 | 0 | 71 |
| Operating income | −80 | −134 | −254 | −299 | −363 |
| Net income | −79 | −130 | −238 | −270 | −343 |
| Free cash flow | −55 | −95 | −185 | −233 | −277 |
Recent filings
- 4Insider transaction report
Aug 20, 2026 - 4Insider transaction report
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KRegulation FD disclosure
Jun 29, 2026 - 8-KResults of a shareholder vote
Jun 3, 2026 - 8-KTermination of a material agreement
May 28, 2026 - 8-KEntry into a material agreement
May 26, 2026